Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:46:34.264Z.
Calculation as of: 2026-10-06T13:46:34.264Z.
Quote observation: 2026-10-06T13:45:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$3.12B
EV/FCF Ratio
81.81x
TTM Avg
109.02x
3Y Avg
109.02x
5Y Avg
109.02x
Market Cap
$3.12B
EV/FCF Ratio
N/A
TTM Avg
15.31x
3Y Avg
19.99x
5Y Avg
19.99x
Market Cap
$3.08B
EV/FCF Ratio
N/A
TTM Avg
34.40x
3Y Avg
34.40x
5Y Avg
34.40x
Market Cap
$3.43B
EV/FCF Ratio
17.87x
TTM Avg
24.95x
3Y Avg
51.13x
5Y Avg
51.13x
Market Cap
$2.89B
EV/FCF Ratio
41.51x
TTM Avg
54.95x
3Y Avg
90.13x
5Y Avg
90.13x
Market Cap
$3.57B
EV/FCF Ratio
N/A
TTM Avg
10.34x
3Y Avg
10.32x
5Y Avg
10.32x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.19B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.12B | 81.81x | 109.02x | 109.02x | 109.02x |
| Denali Therapeutics Inc. (DNLI)vs › | $3.12B | N/A | 15.31x | 19.99x | 19.99x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A | 34.40x | 34.40x | 34.40x |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.43B | 17.87x | 24.95x | 51.13x | 51.13x |
| TransMedics Group, Inc. (TMDX)vs › | $2.89B | 41.51x | 54.95x | 90.13x | 90.13x |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 54.05x | 69.55x | 89.95x | 89.95x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.86B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.57B | N/A | 10.34x | 10.32x | 10.32x |
| Celcuity Inc. (CELC)vs › | $3.54B | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
